Cerus Corp
NASDAQ:CERS

Watchlist Manager
Cerus Corp Logo
Cerus Corp
NASDAQ:CERS
Watchlist
Price: 1.82 USD 3.41% Market Closed
Market Cap: 338m USD
Have any thoughts about
Cerus Corp?
Write Note

Cerus Corp
Income from Continuing Operations

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Cerus Corp
Income from Continuing Operations Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Income from Continuing Operations CAGR 3Y CAGR 5Y CAGR 10Y
Cerus Corp
NASDAQ:CERS
Income from Continuing Operations
-$19.8m
CAGR 3-Years
31%
CAGR 5-Years
22%
CAGR 10-Years
2%
Haemonetics Corp
NYSE:HAE
Income from Continuing Operations
$123.8m
CAGR 3-Years
58%
CAGR 5-Years
13%
CAGR 10-Years
15%
ICU Medical Inc
NASDAQ:ICUI
Income from Continuing Operations
-$111m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Align Technology Inc
NASDAQ:ALGN
Income from Continuing Operations
$441.6m
CAGR 3-Years
-16%
CAGR 5-Years
1%
CAGR 10-Years
12%
Lantheus Holdings Inc
NASDAQ:LNTH
Income from Continuing Operations
$427.6m
CAGR 3-Years
N/A
CAGR 5-Years
65%
CAGR 10-Years
N/A
Merit Medical Systems Inc
NASDAQ:MMSI
Income from Continuing Operations
$120m
CAGR 3-Years
40%
CAGR 5-Years
40%
CAGR 10-Years
19%
No Stocks Found

Cerus Corp
Glance View

Market Cap
337.8m USD
Industry
Health Care

Cerus Corp. engages in the research, development, and manufacturing of biomedical and surgical products. The company is headquartered in Concord, California and currently employs 294 full-time employees. The company is focused on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, which is based on its technology for controlling biological replication, is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. Its INTERCEPT Blood System is intended for use with blood components and certain of their derivatives, such as plasma, platelets, red blood cells. Its product or product candidates under development includes INTERCEPT Blood System-Platelets, INTERCEPT Blood System-Plasma, INTERCEPT Blood System-Red Blood Cells and INTERCEPT Blood System-Cryoprecipitation. The INTERCEPT Blood System is designed to target and inactivate blood-borne pathogens, such as viruses, bacteria and parasites, as well as potentially harmful white blood cells, while preserving the therapeutic properties of platelet, plasma and red blood cell transfusion products.

CERS Intrinsic Value
1.56 USD
Overvaluation 14%
Intrinsic Value
Price

See Also

What is Cerus Corp's Income from Continuing Operations?
Income from Continuing Operations
-19.8m USD

Based on the financial report for Sep 30, 2024, Cerus Corp's Income from Continuing Operations amounts to -19.8m USD.

What is Cerus Corp's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 10Y
2%

Over the last year, the Income from Continuing Operations growth was 60%. The average annual Income from Continuing Operations growth rates for Cerus Corp have been 31% over the past three years , 22% over the past five years , and 2% over the past ten years .

Back to Top